CRL

314.3104.15%
MW

Martin W. MacKay

Co-Founder & Chairman

Dr. Martin W. MacKay, Ph.D., is Director at Sail Biomedicines, Inc. since October 2025. He has been Independent Director at Beeline Medicines Corporation. He had been an Independent Director of SpringWorks Therapeutics, Inc. since July 29, 2024 until July 01, 2025. He is Independent Non-Employee Director of Kailera Therapeutics, Inc. from March 2026. He is Chairman of the Board of Charles River Laboratories International, Inc. since May 05, 2026 and serves as its Independent Director since July 5, 2017. He served as Lead Independent Director of Charles River Laboratories International, Inc. since May 20, 2025 until May 05, 2026.He previously served on the Board of SpringWorks Therapeutics through its acquisition by Merck KGaA in 2025. He is a Co-Founder at Rallybio, LLC and served as its CEO since, 2021 until August 01, 2023. He was Executive Chairman of Rallybio, LLC until December 31, 2024 and serves as its Chairman since December 31, 2024. He had been an Independent Director at 5:01 Acquisition Corp. since October 2020 to April 22, 2022. He is the Co-Founder of Rallybio Corporation and served as its Chief Executive Officer from 2018 until August 01, 2023 and served as Executive Chairman since August 01, 2023 until 2024 and current Non-Executive Chair of Rallybio Corporation and served as Chairman since January 2018 until August 01, 2023. He also served as the Advisor at New Leaf Venture Partners, LLC. He served as a Senior Adviser at New Leaf Venture Partners, LLC from June 4, 2018. He joined New Leaf Venture Partners, LLC on June 4, 2018. He served as Director of Novo Nordisk A/S since March 22, 2018 until November 15, 2025. Previously, Dr. Mackay was Executive Vice President, Global Head of Research and Development at Alexion Pharmaceuticals, Inc. from May 2013 to June 2017. Dr. Mackay served as the President of R&D at AstraZeneca PLC from July 1, 2010 to January 31, 2013. Dr. Mackay led AstraZeneca's research and development organisation and had overall accountability for delivering new products - small molecules and biologics - from its pipeline. Dr. Mackay served as President of PharmaTherapeutics Research & Development at Pfizer Inc. from October 2009 to May 2010. Dr. Mackay served as Head of New Pharmatherapeutics Research Group at Pfizer Inc. since June 2009 and as its Senior Vice President since October 2007 until May 2010. Dr. Mackay served as the President of Pfizer Global Research and Development at Pfizer Inc. since October 4, 2007 until October 2009. He served as a Member of the Executive Leadership Team at Pfizer. He led a global organisation tasked with advancing a portfolio of investigational medicines across a range of disease areas. Dr. Mackay served as Vice President of Global R&D and Senior Vice President of Worldwide Development at Pfizer, where he oversaw 6,500 Pfizer colleagues across clinical development, development operations, pharmaceutical sciences, drug safety and project and portfolio management as well as 11 therapeutic areas. He served as Head of Molecular and Cell Biology, CNS Research at Ciba-Geigy (now Novartis) in the United Kingdom and Switzerland and held positions within academia. He began his career at Pfizer in 1995 as Director of Discovery Biology in the U.K. and held positions of increasing responsibility until he moved to the United States in 1999. Dr. Mackay serves as a Director of Rallybio, LLC. He served as the Senior Vice President and Head of Worldwide Research and Technology at Pfizer since 2003. He served as a Director of ViiV Healthcare Limited. Dr. Mackay served as a Director of Encysive Pharmaceuticals Inc. from April 2008 to June 2008. He conducted his postdoctoral research fellowship in malaria vaccines. Dr. Mackay earned a B.Sc. in Microbiology from Heriot-Watt University and a PhD in Molecular Genetics from the University of Edinburgh in 1984.

Positions